[1]薛 一,孔莫维,高 宇.脂蛋白相关磷脂酶A2与冠心病的研究[J].医学信息,2019,32(12):53-56.[doi:10.3969/j.issn.1006-1959.2019.12.017]
　XUE Yi,KONG Mo-wei,GAO Yu.Research on Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease[J].Journal of Medical Information,2019,32(12):53-56.[doi:10.3969/j.issn.1006-1959.2019.12.017]
点击复制

脂蛋白相关磷脂酶A2与冠心病的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年12期
页码:
53-56
栏目:
综述
出版日期:
2019-06-15

文章信息/Info

Title:
Research on Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease
文章编号:
1006-1959（2019）12-0053-04
作者:
薛 一1; 孔莫维1; 高 宇2
1.承德医学院，河北 承德 067000； 2.承德医学院附属医院内分泌科，河北 承德 067000
Author(s):
XUE Yi1; KONG Mo-wei1; GAO Yu2
1.Chengde Medical College,Chengde 067000,Hebei,China; 2.Department of Endocrinology,Affiliated Hospital of Chengde Medical College,Chengde 067000,Hebei,China
关键词:
脂蛋白相关磷脂酶A2; 冠心病; 动脉粥样硬化
Keywords:
Key words：Lipoprotein-associated phospholipase A2; Coronary heart disease; Atherosclerosis
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2019.12.017
文献标志码:
A
摘要:
在过去的几十年中，炎症在动脉粥样硬化发病机制中的作用一直是研究的热点。研究表明一些炎症标志物对冠心病（CHD）的首发和已确诊CHD患者疾病复发具有预测价值。在这些标记中，脂蛋白相关磷脂酶A2（Lp-PLA2）最近受到了相当的关注。本文对Lp-PLA2作为CHD风险标志物和作为治疗靶点的潜在作用进行综述。
Abstract:
Abstract：In the past few decades, the role of inflammation in the pathogenesis of atherosclerosis has been a hot topic of research. Studies have shown that some inflammatory markers have predictive value for the onset of coronary heart disease (CHD) and the recurrence of disease in patients with confirmed CHD. Among these markers, lipoprotein-associated phospholipase A2 (Lp-PLA2) has recently received considerable attention. This review summarizes the potential role of Lp-PLA2 as a CHD risk marker and as a therapeutic target.

参考文献/References:

[1]Townsend N,Nichols M,Scarborough P,et al.Cardiovascular disease in Europe 2015:epidemiological update[J].Eur Heart J,2015,36(40):2673-2674. [2]Benjamin EJ,Blaha MJ,Chiuve SE,et al.Heart Disease and Stroke Statistics-2017 Update:A Report From the American Heart Association[J].Circulation,2017,135(10):e146-e603. [3]Maeda T,Takeuchi K,Xiaoling P,et al.Lipoprotein-associated phospholipase A2 regulates macrophage apoptosis via the Akt and caspase-7 pathways[J].J Atheroscler Thromb,2014,21(8):839-853. [4]Liu J,Wang W,Qi Y,et al.Association between the lipoprotein-associated phospholipase A2 activity and the progression of subclinical atherosclerosis[J].J Atheroscler Thromb,2014,21(6):532-542. [5]Kinney GL,Snell-Bergeon JK,Maahs DM,et al.Lipoprotein-associated phospholipase A2 activity predicts progression of subclinical coronary atherosclerosis[J].Diabetes Technol Ther,2011,13(3):381-387. [6]Celik O,Ozturk D,Akin F,et al.Evaluation of lipoprotein-associated phosholipase A2 and plaque burden composition in young adults[J].Coron Artery Dis,2015,26(3):266-271. [7]Li DZ,Wei W,Ran X,et al.Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population:A systematic review and meta-analysis[J].Clin Chim Acta,2017,471(5):38-45. [8]Yang L,Liu Y,Wang S,et al.Association between Lp-PLA2 and coronary heart disease in Chinese patients[J].J Int Med Res,2017,45(1):159-169. [9]范艳平,卢经君,唐静怡,等.脂蛋白相关磷脂酶A2水平对老年稳定性冠心病患者心血管事件相关性的临床研究[J].中华老年心脑血管病杂志,2017,19(3):312-313. [10]Thompson A,Gao P,Orfei L,et al.Lipoprotein-associated phospholipase A(2)and risk of coronary disease,stroke,and mortality:Collaborative analysis of 32 prospective studies[J].Lancet,2010,375(9725):1536-1544. [11]Li D,Zhao L,Yu J,et al.Lipoprotein-associated phospholipase A2 in coronary heart disease:Review and meta-analysis[J].Clin Chim Acta,2017,465(12):22-29. [12]Lind L,Simon T,Johansson L,et al.Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities:relation to atherosclerotic plaques and future all-cause mortality[J].Eur Heart J,2012,33(23):2946-2954. [13]Benderly M,Sapir B,Kalter-Leibovici O,et al.Lipoprotein-associated phospholipase A2,and subsequent cardiovascular events and mortality among patients with coronary heart disease[J].Biomarkers,2017,22(3-4):219-224. [14]Ge PC,Chen ZH,Pan RY,et al.Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease:A Multi-Ethnic Study in China[J].Cell Physiol Biochem,2016,40(5):953-968. [15]赵洁,吴俊,贾玫,等.冠心病患者血液脂蛋白相关磷脂酶A2与超敏C反应蛋白及D-二聚体的相关性研究[J].中华检验医学杂志,2014,37(3):227-229. [16]黄立纲,王春燕,刘炼华,等.脂蛋白相关磷脂酶A2与冠心病严重程度的相关性研究[J].中华检验医学杂志,2018,41(6):425-429. [17]Cen JM,Cheng J,Xiong QY,et al.Study on the correlation between the concentration of plasma lipoprotein-associated phospholipase A2 and coronary heart disease[J].Chronic Dis Transl Med,2015,1(2):105-109. [18]Li Y.Analysis of intima-media thickness of carotid artery and lipoprotein-associated phospholipase A2 in coronary heart diseases of different types[J].Technol Health Care,2015,23(Suppl 1):S147-S150. [19]Ma CY,Xu, ZY,Wang SP,et al.Change of Inflammatory Factors in Patients with Acute Coronary Syndrome[J].Chin Med J(Engl),2018,131(12):1444-1449. [20]Ge PC,Chen ZH,Pan RY,et al.Synergistic effect of lipoprotein-associated phospholipase A2 with classical risk factors on coronary heart disease:A multi-ethnic study in China[J].Cell Physiol Biochem,2016,40(5):953-968. [21]Garg PK,McClelland RL,Jenny NS,et al.Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort:The multi ethnic study of atherosclerosis[J].Atherosclerosis,2015,241(1):176-182. [22]Pokharel Y,Sun WS,Polfus LM,et al.Lipoprotein associated phospholipase A2 activity,apolipoprotein C3 loss-of-function variants and cardiovascular disease:The Atherosclerosis Risk In Communities Study[J].Atherosclerosis,2015,241(2):641-648. [23]Ballantyne CM,Hoogeveen RC,Bang H,et al.Lipoprotein-associated phospholipase A2,high-sensitivity C-reactive protein,and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities(ARIC) study[J].Circulation,2004,109(7):837-842. [24]Rana JS,Arsenault BJ,Després JP,et al.Inflammatory biomarkers,physical activity,waist circumference,and risk of future coronary heart disease in healthy men and women[J].Eur Heart J,2011,32(3):336-344. [25]Corsetti JP,Rainwater DL,Moss AJ,et al.High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients[J].Clin Chem,2006,52(7):1331-1338. [26]Gregson JM,Freitag DF,Surendran P,et al.Genetic invalidation of Lp-PLA2 as a therapeutic target:Large-scale study of five functional Lp-PLA2-lowering alleles[J].Eur J Pre Cardiol,2017,24(5):492-504. [27]Li L,Qi L,Lv N,et al.Association between lipoprotein-associated phospholipase A2 gene polymorphism and coronary artery disease in the Chinese Han population[J].Ann Hum Genet,2011,75(5):605-611. [28]Millwood IY,Bennett DA,Walters RG,et al.A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults[J].Int J Epidemiol,2016,45(5):1588-1599. [29]岳志红,菅广敏,贾玫,等.脂蛋白相关磷脂酶A2酶活性水平及其I198T基因多态性与冠心病的相关性研究[J].中华检验医学杂志,2013,36(2):156-160. [30]Johnson JL,Shi Y,Snipes R,et al.Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity:A randomized,controlled trial[J].PLoS One,2014,9(2):e89034. [31]White HD,Held C,Stewart R,et al.Darapladib for preventing ischemic events in stable coronary heart disease[J].N Engl J Med,2014,370(18):1702-1711. [32]O'Donoghue ML,Braunwald E,White HD,et al.Effect of darapladib on major coronary events after an acute coronary syndrome:The SOLID-TIMI 52 randomized clinical trial[J].JAMA,2014,312(10):1006-1015.

相似文献/References:

[1]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,31(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
　YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Journal of Medical Information,2018,31(12):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[2]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,31(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
　ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Journal of Medical Information,2018,31(12):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[3]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,31(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
　ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Journal of Medical Information,2018,31(12):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[4]张 旭.冠心病心绞痛患者进行护理干预的临床效果及 对护理质量影响研究[J].医学信息,2018,31(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
　ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Journal of Medical Information,2018,31(12):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[5]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
　XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Journal of Medical Information,2018,31(12):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[6]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与 冠状动脉病变程度的关系[J].医学信息,2018,31(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
　WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Journal of Medical Information,2018,31(12):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[7]毛红岩.冠状动脉介入治疗冠心病的疗效及 对患者血清炎症因子的影响[J].医学信息,2018,31(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
　MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Journal of Medical Information,2018,31(12):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[8]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与 冠状动脉病变程度的相关性研究[J].医学信息,2018,31(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
　YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Journal of Medical Information,2018,31(12):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[9]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
　LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Journal of Medical Information,2018,31(12):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[10]田跃雷.冠心病介入治疗后再狭窄的中西医防治[J].医学信息,2022,35(09):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
　TIAN Yue-lei.Prevention and Treatment of Restenosis After Percutaneous Coronary Intervention with Chinese and Western Medicine[J].Journal of Medical Information,2022,35(12):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]

更新日期/Last Update: 2019-06-15